Worcester, MA – CBRE announced that it has arranged the sale of a 6.8 acre parcel of land at The Reactory, a 46-acre master-planned biomanufacturing campus, to WuXi Biologics, a global company with leading open-access biologics technology platforms.
WuXi Biologics plans to build a 107,000 sq. ft., two-story facility, which will serve as the anchor project at The Reactory campus. The facility is expected to be completed by 2022 and bring 150 new jobs to the Worcester, MA area.
CBRE’s Brian Cohen, Chris McCauley and Colin Coughlin represented WuXi Biologics, the buyer, which acquired the parcel from New Garden Park, Inc.
“We are pleased to have completed such a significant transaction marking WuXi Biologics’ continued U.S. market expansion and solid growth of Worcester’s life sciences sector,” said CBRE’s Cohen. “The support of the City of Worcester and the Commonwealth of Massachusetts were instrumental in this transformative deal, which will bring a substantial amount of new biologics manufacturing space, jobs and investment to the area.”
Headquartered in China, WuXi Biologics is a leading global open-access biologics technology platform designed to provide one-stop service solutions that empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. With over 250 integrated biomanufacturing projects in various development stages, WuXi Biologics plans to continue the expansion of its production base in Europe and the United States.
Located on the former Worcester State Hospital site, The Reactory is a 46-acre campus dedicated to offering biomanufacturing space that is high quality, cost-effective and within close proximity to innovative clinical research. The Reactory’s master plan allows for eight parcels that can accommodate up to 470,000 sq. ft. of manufacturing facilities less than one hour from Kendall Square.
